Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study

ConclusionsThis study demonstrates that the risk of developing a second IMID is significantly higher for individuals who have already experienced a first IMID in a large and contemporary US claims database. Certain pairs of IMIDs co-occur more frequently than others. The risk of developing subsequent IMIDs may be an important consideration for clinicians when selecting treatment strategies.FundingAbbvie.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research

Related Links:

Conclusions: With a 15% incidence of occult posterior malleolar fractures, a CT scan or multiple orthogonal views can be helpful to avoid missed fractures. Given the wide variability of fracture angle, a single external rotation view is unlikely to prevent all missed fractures on initial radiographic interpretations. Level of Evidence: Level III, retrospective cohort study.
Source: Current Orthopaedic Practice - Category: Orthopaedics Tags: Special Focus: Resident Research Award Source Type: research
No abstract available
Source: Current Orthopaedic Practice - Category: Orthopaedics Tags: Case Report Source Type: research
Publication date: Available online 22 June 2019Source: PharmaNutritionAuthor(s): Srijita Sireswar, Ishita Ghosh, Gargi DeyAbstractThe interaction between the intestinal biota and humans have co-evolved, directing both to a state of complementary tolerance. However, dysbiosis in intestinal microbiota leads to inflammatory bowel disease which results from an aggressive immune response towards specific components of the commensal, enteric bacteria in a genetically susceptible host. One of the popular strategies for prophylaxis and treatment of inflammatory bowel disease has been the use of immune-regulatory probiotic formulat...
Source: PharmaNutrition - Category: Nutrition Source Type: research
ANAHEIM, CA - More outreach is needed to explain the value of nuclear medicine...Read more on AuntMinnie.comRelated Reading: SNMMI: PET ligand can diagnose brain disorder before autopsy SNMMI: PET ligand can diagnose brain disorder before autopsy SNMMI: Technetium radiotracer tracks rheumatoid arthritis SNMMI: FDG-PET/MRI improves pain diagnosis, management Video from SNMMI 2019: Dr. Barry Siegel on PET reimbursement
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Higher intake of gluten early in life is associated with an increased risk of celiac disease (CD) and CD autoimmunity, according to new findings.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
ANAHEIM, CA - Having a lecture at a major medical conference named after you...Read more on AuntMinnie.comRelated Reading: SNMMI: PET ligand can diagnose brain disorder before autopsy SNMMI: Technetium radiotracer tracks rheumatoid arthritis SNMMI: FDG-PET/MRI improves pain diagnosis, management Video from SNMMI 2019: Outreach needed to tell discipline's story
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Doctors who treated the man in Missouri believe the high-fibre diet could be beneficial for people with Crohn's. But other experts warn against such drastic measures.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
Bristol-Myers Squibb said it is planning to sell Otezla, Celgene's treatment for certain types of psoriasis and psoriatic arthritis, in an effort to address Federal Trade Commission concerns about its pending merger with Celgene.
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news
ConclusionsThis study indicates that there was no significant correlation between IgG antibodies against Toxocara and variables such as gender and age. Based on the statistical analysis, there was no significant difference in Toxocara seropositivity between our control population with MS and RA patients.
Source: Clinical Epidemiology and Global Health - Category: Epidemiology Source Type: research
To satisfy concerns raised by the U.S. Federal Trade Commission, Bristol-Myers Squibb Co. said it will divest Celgene Corp.'s Otezla psoriasis treatment. In January, New York City-based Bristol-Myers Squibb (NYSE: BMY) said it was buying Summit, New Jersey-based Celgene (Nasdaq: CELG) in a cash-and-stock deal worth about $74 billion. In March, the FTC requested additional information from the companies regarding their marketed and pipeline product s for the treatment of psoriasis. "To allow the…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
More News: Ankylosing Spondylitis | Arthritis | Celiac Disease | Coeliac Disease | Databases & Libraries | Drugs & Pharmacology | Environmental Health | Genetics | Health Insurance | Hidradenitis | Inflammatory Bowel Disease | Insurance | Lupus | Psoriasis | Psoriatic Arthritis | Rheumatology | Study